BIONTECH SE SPON. ADRS 1
Commented by André Will-Laudien on October 14th, 2021 | 11:27 CEST
BioNTech, Cardiol Therapeutics, CureVac: A decade's worth of ideas!
Biotechnology remains a hotly contested industry. In the fight against a wide range of diseases, biopharmaceuticals are the first port of call. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. By directly applying findings from biology and biochemistry, technically functional elements are identified. The central objectives are to research, improve and develop processes for the production of relevant substances. Often research goes nowhere; we take a look at the sector.
Read
Commented by Carsten Mainitz on October 12th, 2021 | 12:32 CEST
Defence Therapeutics, BioNTech, Valneva - When will things pick up again?
Biotechnology companies can experience a significant, sometimes even exponential, increase in value virtually overnight with a new, successful active ingredient. BioNTech is a prime example of this. But not every research effort leads to success, and CureVac shareholders can tell you a thing or two about that. Canada's Defence Therapeutics and Valneva have innovative research pipelines. Where should investors consider investing now?
Read
Commented by André Will-Laudien on October 8th, 2021 | 10:25 CEST
BioNTech, Defence Therapeutics, Valneva, Formycon - Close to the bio-revolution!
Portugal is one of the countries with the highest vaccination rate, with 86% of the population already vaccinated. Approximately 98% of those eligible for vaccination - including everyone over the age of 12 - have been vaccinated. Germany, with about 64%, is one of the more vaccine-weary nations. What is the secret of the Portuguese? The government relied on an opinion maker from within its ranks, Admiral Gouveia e Melo. An expert in complicated logistical tasks in the military, he was appointed in February as the top leader of the national vaccination campaign. He is never seen without his military combat uniform in numerous public television appearances - and when asked how other countries can move their own vaccination effort forward, the admiral did not hesitate to offer his best advice: "You have to find people who are not politicians." Where are the current opportunities in the vaccination sector?
Read
Commented by Armin Schulz on October 6th, 2021 | 12:32 CEST
Valneva, Cardiol Therapeutics, BioNTech - New vaccines needed against Corona
Johnson & Johnson's new study shows the booster vaccine improves protection against severe Corona disease by 75%. According to the New York Times, the Company plans to seek approval for the booster vaccine. While the FDA has already approved BioNTech's booster vaccine for those over 65, Moderna and Johnson & Johnson have yet to receive approvals. Those are on the agency's Oct. 14 and 15 meeting schedule. BioNTech CEO Ugur Sahin stressed to the Financial Times that there must always be new formulations to stop new virus variants.
Read
Commented by Fabian Lorenz on October 5th, 2021 | 11:40 CEST
BioNTech, Varta, Sierra Grande Minerals - Is the countermovement coming?
The BioNTech share was under intense pressure in the past trading week. But even at the start of the week, the bulls could not prevail with a countermovement. There is also good news from the new German biotech star. Ripe for a rebound are also the shares of Varta and Sierra Grande. At Varta, the presentation of Apple's new Airpods could herald a share price recovery. Sierra Grande is suffering from weak precious metal prices. The Company has just published positive drilling results. Investors could soon look forward to rising prices for all three shares.
Read
Commented by Stefan Feulner on September 30th, 2021 | 12:20 CEST
BioNTech, Sativa Wellness Group, Aurora Cannabis - For the good of humanity
One thing has been brought home to humanity since the outbreak of the Corona Pandemic and the rapid development of vaccines - Science and research are essential in identifying health risks and helping people live long and healthy lives. Young companies, in particular, are discovering alternative treatments through their research and using natural products that have centuries of tradition - with great potential.
Read
Commented by Carsten Mainitz on September 28th, 2021 | 11:19 CEST
Cardiol Therapeutics, BioNTech, Valneva - Volatility offers good opportunities!
The share prices of the Corona vaccine manufacturers are not growing sky-high after all. Most recently, developments at France's Valneva caused uncertainty. The French Company wanted to bring a Corona vaccine to market by the end of 2021 and had already received an order from the British government for 100 million units. This contract has now been canceled. Where does the industry go from here?
Read
Commented by Nico Popp on September 27th, 2021 | 10:46 CEST
BioNTech, Meta Materials, Bayer: Rich with innovations
A new car manufacturer or a new networked fitness device can trigger hype on the stock market. But the opportunities are even greater when companies bring genuine innovations to market. These include new active ingredients, pharmacological processes or pioneering achievements by engineers. We present innovators of yesterday, today and tomorrow and shed light on their growth prospects.
Read
Commented by Fabian Lorenz on September 24th, 2021 | 14:10 CEST
BioNTech, Valneva, Defence Therapeutics: New highs for vaccine stocks?
Investors in COVID-19 vaccine manufacturers have had little reason to rejoice in recent weeks. Top dogs Moderna and BioNTech have come back noticeably from their highs. Valneva's stock plummeted on Monday. Only newcomer Defence Therapeutics has held its ground at a high level. But for all of them, the calm could soon be over, and a new high could begin. Because people in other parts of the world are still not vaccinated. In addition, winter is just around the corner in Western countries, which means that Corona rates are rising. In addition, a new study shows the risk of long-COVID - such as memory and concentration deficits - even in children. With this mix, vaccine stocks face an exciting fall.
Read
Commented by Stefan Feulner on September 20th, 2021 | 12:05 CEST
Valneva, Cardiol Therapeutics, BioNTech - Recurring businesses
The vaccination rate is stalling. Around 4 million out of 24 million people over the age of 60 are still unvaccinated. Politicians led by Health Minister Jens Spahn have now launched a vaccination campaign week to get more people immunized against the coronavirus. The proportion of vaccinated people in Germany is still too low to prevent a new Corona wave and a possible resulting overload of the healthcare system. Meanwhile, vaccine producers are already working on the approval of booster shots. Profits should continue to bubble up for a long time.
Read